TrialJournal of neuro-oncology2019

Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.

Kiyong Na et al.PubMed ↗Publisher ↗

No numbers read from the abstract.